Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SPCEO1on Jul 14, 2021 11:05am
232 Views
Post# 33542196

What tomorrow may bring

What tomorrow may bringI am guessing not much.

On the legacy business, I am not expecting anything that would be unusually good or unusually bad. Unfirtunately, because TH has been unabel to get all the analysts to produce sensible forecasts, we are most likely going to see headlines yet again that TH missed on both the top and bottom lines tomorrow morning. Really, it is more that some of the analysts have missed the mark more than the company but the company should do whatever is necessary, most notably ny providing guidance, to make sure such a situation never happens. But for reasons that escape me, TH never does that and instead is content to see analysts continuously have bad estimates which leads directly to those headlines about how TH came up short of expectations. 

On NASH, we should get some sort of update but given that we have not heard much about it, Logterm's concern about the start date for the phase III being pushed back seems like a reasonable assumption.

On cancer, the best we can likely hope for is hints that  e discern from reading between the lines. Only us on this board will be even trying to discern such hints and if we do get any, we are the only ones who will likely react to them. If TH wants the stock price to react to any cancer news, they are going to have to be really straightforward about whatever they say, and even then they might not get much of a reaction since the analysts are unlikely to start incorporating anything for cnacer into their models until at least the first part of the pahse I trial is complete and maybe not until the second part. Moreover, the analysts covering TH are not cancer  experts and do not have a bunch of institutions lookinig to t hem for their cancer expertise. So, whenever there is some interesting cancer data, don't be surprised if we all recognize it as very meaningful while the stock price takes much longer for it to react to it.  

I am going to be interested to see what the cash burn rate was during the quarter and also in how many follish retial investors converted their warrants.

But I am not expecting much stock reaction tomorrow if they have nothing to excite the market on the cancer front. 
<< Previous
Bullboard Posts
Next >>